This article was published in Anti Age Magazine Volume #48. We would like to thank Dr. Ascher and Anti Age Magazine for sharing it with the international community.
The botulinum toxins Onabotulinum/Botox®, Abobotulinum/ Dysport® and Incobotulinum/Xéomin® have been used for the last 5 to 10 years. Neubotulinum/Neuronox®, Letibotulinumtoxin/Botulax® and Prabotulinumtoxin/Neuceiva® are set to considerably increase the offer in France and Europe. Botulax® from Hugel Pharma, which was approved in Korea in 2010, will be commercialized by Croma Pharma, as will Nuceiva®, the European name for Jeauveau®, which is currently distributed in the United States and Canada by Evolus. A bit further in the future, Daxi® by Revance should be launched in Europe by Teoxane in 2025.
It will be interesting to follow these new releases closely, as they are set to challenge the toxins that are already established as well as being priced more attractively. Note that these toxins are all serious products whose safety has been fully approved.
The current revolution: the liquid form
What we are currently interested in are the liquid forms of toxins, which are a real revolution. This “ready to use” format has already been used in Korea since 2013 – with Innotox® from Meditox – and has just been joined by the liquid form of Azzalure, Alluzience®, which is produced by Ipsen.The advantage of a liquid is that it deposits an identical dose in each injection and means we do not have to add any animal protein. We also have a good idea of how long it will last, which is important, especially for the glabellar.
What are the next steps?
The Ipsen laboratory is working on a so-called “fast-action” toxin, a recombination of type E. It is produced by the E. Coli bacteria instead of Clostridium and allows us to achieve the effects after just a few hours instead of a few days, like with other toxins. A lot of modified hybrid forms are in the pipeline, and in the THINKIN center this October we are studying a “modified” AB toxin which should offer a significantly increased duration of action.
If everyone has the increased safety of injections as their goal, the arrival of these new toxins and innovations on the European market should allow us to reduce the price of the products and therefore of the injections, and increase their duration of action.
Etiquetas: Inyecciones
Share this article on
